These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34483276)

  • 1. Effect of Azithromycin on the Ocular Surface Microbiome of Children in a High Prevalence Trachoma Area.
    Doan T; Gebre T; Ayele B; Zerihun M; Hinterwirth A; Zhong L; Chen C; Ruder K; Zhou Z; Emerson PM; Porco TC; Keenan JD; Lietman TM
    Cornea; 2022 Oct; 41(10):1260-1264. PubMed ID: 34483276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotics for trachoma.
    Evans JR; Solomon AW; Kumar R; Perez Á; Singh BP; Srivastava RM; Harding-Esch E
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD001860. PubMed ID: 31554017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
    Keenan JD; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Emerson PM; Callahan K; Cotter SY; Stoller NE; Porco TC; Oldenburg CE; Lietman TM
    PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of Mass Azithromycin Distribution for Ocular Chlamydia in a Trachoma Endemic Region of Ethiopia: A Cluster Randomized Trial.
    Lietman TM; Ayele B; Gebre T; Zerihun M; Tadesse Z; Emerson PM; Nash SD; Porco TC; Keenan JD; Oldenburg CE
    Am J Ophthalmol; 2020 Jun; 214():143-150. PubMed ID: 32171768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Biannual Mass Azithromycin Distributions to Preschool-Aged Children on Trachoma Prevalence in Niger: A Cluster Randomized Clinical Trial.
    Arzika AM; Mindo-Panusis D; Abdou A; Kadri B; Nassirou B; Maliki R; Alsoudi AF; Zhang T; Cotter SY; Lebas E; O'Brien KS; Callahan EK; Bailey RL; West SK; Goodhew EB; Martin DL; Arnold BF; Porco TC; Lietman TM; Keenan JD;
    JAMA Netw Open; 2022 Aug; 5(8):e2228244. PubMed ID: 35997979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The conjunctival microbiome before and after azithromycin mass drug administration for trachoma control in a cohort of Tanzanian children.
    Pickering H; Ramadhani AM; Massae P; Mafuru E; Malisa A; Mbuya K; Makupa W; Mtuy T; Derrick T; Houghton J; Bailey RL; Mabey DCW; Burton MJ; Holland MJ
    Front Public Health; 2022; 10():1015714. PubMed ID: 36324475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Antibiotics for Trachoma: A Cluster-Randomized Trial.
    Melo JS; Aragie S; Chernet A; Tadesse Z; Dagnew A; Hailu D; Haile M; Zeru T; Wittberg DM; Nash SD; Callahan EK; Arnold BF; Porco TC; Lietman TM; Keenan JD
    Clin Infect Dis; 2021 Sep; 73(6):979-986. PubMed ID: 33674869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Mass Azithromycin Distribution for Trachoma: A Community-Randomized Trial (TANA II).
    Mahmud H; Haile BA; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Liu Z; Callahan EK; Cotter SY; Varnado NE; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
    Clin Infect Dis; 2023 Aug; 77(3):388-395. PubMed ID: 37021692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.
    Morberg DP; Alemayehu W; Melese M; Lakew T; Sisay A; Zhou Z; Cevallos V; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
    Ophthalmic Epidemiol; 2019 Feb; 26(1):19-26. PubMed ID: 30153085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Antibiotic Selection Pressure on the Nasopharyngeal Macrolide Resistome: A Cluster-randomized Trial.
    Keenan JD; Chin SA; Amza A; Kadri B; Nassirou B; Cevallos V; Cotter SY; Zhou Z; West SK; Bailey RL; Porco TC; Lietman TM;
    Clin Infect Dis; 2018 Nov; 67(11):1736-1742. PubMed ID: 29897440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Mass Azithromycin Coverage Targets of Children in Niger: A Cluster-Randomized Trachoma Trial.
    Oldenburg CE; Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Gaynor BD; Keenan JD; Lietman TM
    Am J Trop Med Hyg; 2018 Feb; 98(2):389-395. PubMed ID: 29260659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.
    Porco TC; Gebre T; Ayele B; House J; Keenan J; Zhou Z; Hong KC; Stoller N; Ray KJ; Emerson P; Gaynor BD; Lietman TM
    JAMA; 2009 Sep; 302(9):962-8. PubMed ID: 19724043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for ocular chlamydia after three mass azithromycin distributions.
    Ayele B; Gebre T; Moncada J; House JI; Stoller NE; Zhou Z; Porco TC; Gaynor BD; Emerson PM; Schachter J; Keenan JD
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1441. PubMed ID: 22180804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger.
    Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Keenan JD; Lietman TM; Oldenburg CE
    Ophthalmic Epidemiol; 2019 Aug; 26(4):231-237. PubMed ID: 30957594
    [No Abstract]   [Full Text] [Related]  

  • 15. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
    West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J
    J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
    West SK; Munoz B; Mkocha H; Gaydos C; Quinn T
    Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1492-7. PubMed ID: 17389476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.
    Wilson N; Goodhew B; Mkocha H; Joseph K; Bandea C; Black C; Igietseme J; Munoz B; West SK; Lammie P; Kasubi M; Martin DL
    Ophthalmic Epidemiol; 2019 Feb; 26(1):1-6. PubMed ID: 30543311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
    JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for active trachoma and Chlamydia trachomatis infection in rural Ethiopia after mass treatment with azithromycin.
    Edwards T; Harding-Esch EM; Hailu G; Andreason A; Mabey DC; Todd J; Cumberland P
    Trop Med Int Health; 2008 Apr; 13(4):556-65. PubMed ID: 18282237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass drug administration of azithromycin for trachoma reduces the prevalence of genital Chlamydia trachomatis infection in the Solomon Islands.
    Marks M; Bottomley C; Tome H; Pitakaka R; Butcher R; Sokana O; Kako H; Solomon AW; Mabey DC
    Sex Transm Infect; 2016 Jun; 92(4):261-5. PubMed ID: 26888658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.